keyword
Keywords Chronic kidney disease managem...

Chronic kidney disease management and treatment

https://read.qxmd.com/read/38609756/non-valvular-atrial-fibrillation-in-patients-on-peritoneal-dialysis-prevalence-treatment-and-professionals-involved
#41
JOURNAL ARTICLE
Elisa Perez-Bernat, M ª Angeles Viñas, Manel Vera, Miguel González-Rico, Marco Montomoli, Elena Astudillo-Cortés, Juan Carlos Quevedo-Reina, Isabel García-Méndez, Adoración Martinez-Losa, Ines Rama-Arias, María Maldonado-Martín, M ª Antonia Munar, Agustín Ortega Cerrato, Sandra Beltrán-Catalán, Gloria Del Peso, Aleix Cases, Jose Luis Górriz
Atrial fibrillation is the most frequent chronic arrhythmia in patients with chronic kidney disease. Oral anticoagulation with vitamin K antagonists and now direct oral anticoagulants have been and are the fundamental pillars for the prevention of thromboembolic events. However, there are no randomized clinical trials on the risk-benefit profile of oral anticoagulation in patients with chronic kidney disease stage 5 on peritoneal dialysis and there is little evidence in the literature in this population. The objective of our study was to know the prevalence, treatment and professionals involved in the management of atrial fibrillation in peritoneal dialysis patients...
April 11, 2024: Nefrología
https://read.qxmd.com/read/38598905/predictive-analytics-support-for-complex-chronic-medical-conditions-an-experience-based-co-design-study-of-physician-managers-needs-and-preferences
#42
JOURNAL ARTICLE
Muhammad Rafiq, Pamela Mazzocato, Christian Guttmann, Jonas Spaak, Carl Savage
PURPOSE: The literature suggests predictive technology applications in health care would benefit from physician and manager input during design and development. The aim was to explore the needs and preferences of physician managers regarding the role of predictive analytics in decision support for patients with the highly complex yet common combination of multiple chronic conditions of cardiovascular (Heart) and kidney (Nephrology) diseases and diabetes (HND). METHODS: This qualitative study employed an experience-based co-design model comprised of three data gathering phases: 1...
April 7, 2024: International Journal of Medical Informatics
https://read.qxmd.com/read/38595915/unveiling-the-anticancer-effects-of-sglt-2i-mechanisms-and-therapeutic-potential
#43
REVIEW
Min Sun, Jilei Sun, Wei Sun, Xiaonan Li, Zhe Wang, Liwei Sun, Yuehui Wang
Cancer and diabetes are significant diseases that pose a threat to human health. Their interconnection is complex, particularly when they coexist, often necessitating multiple therapeutic approaches to attain remission. Sodium-glucose cotransporter protein two inhibitors (SGLT-2i) emerged as a treatment for hyperglycemia, but subsequently exhibited noteworthy extra-glycemic properties, such as being registered for the treatment of heart failure and chronic kidney disease, especially with co-existing albuminuria, prompting its assessment as a potential treatment for various non-metabolic diseases...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38592300/effect-of-denosumab-on-bone-health-vascular-calcification-and-health-related-quality-of-life-in-hemodialysis-patients-with-osteoporosis-a-prospective-observational-study
#44
JOURNAL ARTICLE
Hyunsook Kim, Eun Ju Lee, Siyun Woo, Sohee Rho, Ji Yong Jung
Background : Osteoporosis is common in hemodialysis (HD) patients, contributing to cardiovascular risks. Limited research exists on denosumab's efficacy in this group. Our study explores denosumab's effects on bone turnover markers (BTMs) and vascular calcification in chronic kidney disease-mineral bone disorder (CKD-MBD) patients. Methods : In a prospective single-center study, we investigated the effects of denosumab over 2 years on 30 HD patients from a cohort of 185. Annual assessments of bone mineral density (BMD), vascular calcification, and health-related quality of life (HRQL) were conducted and compared with an untreated group...
March 2, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38592263/displacing-the-burden-a-review-of-protein-bound-uremic-toxin-clearance-strategies-in-chronic-kidney-disease
#45
REVIEW
Didier Sánchez-Ospina, Sebastián Mas-Fontao, Carolina Gracia-Iguacel, Alejandro Avello, Marina González de Rivera, Maddalen Mujika-Marticorena, Emilio Gonzalez-Parra
Uremic toxins (UTs), particularly protein-bound uremic toxins (PBUTs), accumulate in chronic kidney disease (CKD) patients, causing significant health complications like uremic syndrome, cardiovascular disease, and immune dysfunction. The binding of PBUTs to plasma proteins such as albumin presents a formidable challenge for clearance, as conventional dialysis is often insufficient. With advancements in the classification and understanding of UTs, spearheaded by the European Uremic Toxins (EUTox) working group, over 120 molecules have been identified, prompting the development of alternative therapeutic strategies...
March 1, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38592214/type-2-diabetes-and-chronic-kidney-disease-an-opportunity-for-pharmacists-to-improve-outcomes
#46
REVIEW
Joshua J Neumiller, Wendy L St Peter, Jay H Shubrook
Chronic kidney disease (CKD) is an important contributor to end-stage kidney disease, cardiovascular disease, and death in people with type 2 diabetes (T2D), but current evidence suggests that diagnosis and treatment are often not optimized. This review examines gaps in care for patients with CKD and how pharmacist interventions can mitigate these gaps. We conducted a PubMed search for published articles reporting on real-world CKD management practice and compared the findings with current recommendations. We find that adherence to guidelines on screening for CKD in patients with T2D is poor with particularly low rates of testing for albuminuria...
February 28, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38591086/acute-worsening-of-microvascular-complications-of-diabetes-mellitus-during-rapid-glycemic-control-the-pathobiology-and-therapeutic-implications
#47
EDITORIAL
Dania Blaibel, Cornelius James Fernandez, Joseph M Pappachan
While chronic hyperglycaemia resulting from poorly controlled diabetes mellitus (DM) is a well-known precursor to complications such as diabetic retinopathy, neuropathy (including autonomic neuropathy), and nephropathy, a paradoxical intensification of these complications can rarely occur with aggressive glycemic management resulting in a rapid reduction of glycated haemoglobin. Although, acute onset or worsening of retinopathy and treatment induced neuropathy of diabetes are more common among these complications, rarely other problems such as albuminuria, diabetic kidney disease, Charcot's neuroarthropathy, gastroparesis, and urinary bladder dysfunction are also encountered...
March 15, 2024: World Journal of Diabetes
https://read.qxmd.com/read/38590481/the-role-of-telemedicine-in-enhancing-chronic-kidney-disease-ckd-management-and-dialysis-care
#48
EDITORIAL
Ramchandani Santosh, Yaqub Nadeem Mohammed, Zubair Rahaman, Sakshi Khurana
Telemedicine has emerged as a transformative solution in the realm of healthcare, particularly in addressing the complexities and challenges associated with chronic kidney disease (CKD) and dialysis care. This editorial explores the potential of telemedicine in revolutionizing the management and treatment of kidney diseases, highlighting its role in mitigating the burdens faced by healthcare systems worldwide. With the advent of high-quality audio and visual platforms, telemedicine has facilitated remote healthcare delivery, enabling healthcare professionals to provide exceptional care from a distance...
March 2024: Curēus
https://read.qxmd.com/read/38589290/novel-potential-therapeutic-targets-in-autosomal-dominant-polycystic-kidney-disease-from-the-perspective-of-cell-polarity-and-fibrosis
#49
JOURNAL ARTICLE
Yejin Ahn, Jong Hoon Park
Autosomal dominant polycystic kidney disease (ADPKD), a congenital genetic disorder, is a notable contributor to the prevalence of chronic kidney disease worldwide. Despite the absence of a complete cure, ongoing research aims for early diagnosis and treatment. Although agents such as tolvaptan and mTOR inhibitors have been utilized, their effectiveness in managing the disease during its initial phase has certain limitations. This review aimed to explore new targets for the early diagnosis and treatment of ADPKD, considering ongoing developments...
April 9, 2024: Biomolecules & Therapeutics
https://read.qxmd.com/read/38583146/randomized-evaluation-of-a-remote-management-program-to-improve-guideline-directed-medical-therapy-the-diabetes-remote-intervention-to-improve-use-of-evidence-based-medications-drive-trial
#50
JOURNAL ARTICLE
Alexander J Blood, Lee-Shing Chang, Shahzad Hassan, Jacqueline Chasse, Gretchen Stern, Daniel Gabovitch, David Zelle, Caitlin Colling, Samuel J Aronson, Christian Figueroa, Emma Collins, Ryan Ruggiero, Emily Zacherle, Josh Noone, Carey Robar, Jorge Plutzky, Thomas A Gaziano, Christopher P Cannon, Deborah J Wexler, Benjamin M Scirica
BACKGROUND: Several sodium-glucose transport protein 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce cardiovascular (CV) events and improve kidney outcomes in patients with type 2 diabetes (T2D); however, utilization remains low despite guideline recommendations. METHODS: A randomized, remote implementation trial in the Mass General Brigham network enrolled patients with T2D at high CV and /or kidney risk. Patients eligible for, but not prescribed, SGLT2i or GLP-1 RA were randomly assigned to simultaneous virtual patient education with concurrent prescription of SGLT2i or GLP-1 RA ("simultaneous") or two months of virtual education followed by medication prescription ("education-first") delivered by a multi-disciplinary team driven by non-licensed navigators and clinical pharmacists who prescribed SGLT2i or GLP-1 RA using a standardized treatment algorithm...
April 7, 2024: Circulation
https://read.qxmd.com/read/38578541/apasl-clinical-practice-guidelines-on-the-management-of-acute-kidney-injury-in-acute-on-chronic-liver-failure
#51
EDITORIAL
Rakhi Maiwall, Satender Pal Singh, Paolo Angeli, Richard Moreau, Aleksander Krag, Virender Singh, Ashwani K Singal, S S Tan, Puneet Puri, Mamun Mahtab, George Lau, Qin Ning, Manoj Kumar Sharma, P N Rao, Dharmesh Kapoor, Subhash Gupta, Ajay Duseja, Manav Wadhawan, Dinesh Jothimani, Sanjiv Saigal, Sunil Taneja, Akash Shukla, Pankaj Puri, Deepak Govil, Gaurav Pandey, Kaushal Madan, C E Eapen, Jaya Benjamin, Ashok Chowdhury, Shweta Singh, Vaishali Salao, Jin Mo Yang, Saeed Hamid, Shalimar, Sanjiv Jasuja, Anand V Kulkarni, Madund A Niriella, Harsh Vardhan Tevethia, Vinod Arora, R P Mathur, Akash Roy, Ankur Jindal, Neeraj Saraf, Nipun Verma, Arka De, Narendra S Choudhary, Rohit Mehtani, Phool Chand, Omkar Rudra, Shiv Kumar Sarin
Acute-on-chronic liver failure (ACLF) is a syndrome that is characterized by the rapid development of organ failures predisposing these patients to a high risk of short-term early death. The main causes of organ failure in these patients are bacterial infections and systemic inflammation, both of which can be severe. For the majority of these patients, a prompt liver transplant is still the only effective course of treatment. Kidneys are one of the most frequent extrahepatic organs that are affected in patients with ACLF, since acute kidney injury (AKI) is reported in 22...
April 5, 2024: Hepatology International
https://read.qxmd.com/read/38577748/tolvaptan-therapy-for-edema-in-patients-with-chronic-kidney-disease
#52
JOURNAL ARTICLE
Li Zhou, Qianqian Xu, Xuehua Xi, Xueying Yu, Wenge Li
OBJECTIVE: Tolvaptan is a vasopressin V2 receptor antagonist that is commonly prescribed to alleviate edema associated with renal diseases. However, the clinical benefits of tolvaptan in chronic kidney disease (CKD) remain unclear. This study aimed to evaluate the effectiveness of tolvaptan in managing edema caused by CKD. MATERIALS AND METHODS: The efficacy and treatment regimen of tolvaptan were assessed in a cohort of 96 patients with renal edema and CKD. During the treatment, the patients' creatinine (CR), uric acid (UA), and estimated glomerular filtration rate (eGFR) were monitored as important indicators of kidney function...
April 5, 2024: Clinical Nephrology
https://read.qxmd.com/read/38577536/palliative-long-term-abdominal-drains-vs-large-volume-paracenteses-for-the-management-of-refractory-ascites-in-end-stage-liver-disease
#53
JOURNAL ARTICLE
Senamjit Kaur, Rodrigo V Motta, Bryony Chapman, Victoria Wharton, Jane D Collier, Francesca Saffioti
BACKGROUND: Long-term abdominal drains (LTAD) are a cost-effective palliative measure to manage malignant ascites in the community, but their use in patients with end-stage chronic liver disease and refractory ascites is not routine practice. The safety and cost-effectiveness of LTAD are currently being studied in this setting, with preliminary positive results. We hypothesised that palliative LTAD are as effective and safe as repeat palliative large volume paracentesis (LVP) in patients with cirrhosis and refractory ascites and may offer advantages in patients' quality of life...
March 27, 2024: World Journal of Hepatology
https://read.qxmd.com/read/38571853/apixaban-induced-spontaneous-hemorrhagic-cardiac-tamponade
#54
Jeewan Ambat, Siddharth Patel, Prutha R Pathak, McAnto Antony, Ashish K Basu, Francis G Sto Domingo, Paul Q Vu
Direct oral anticoagulants (DOACs), such as apixaban, are used for the prevention and management of thromboembolic diseases. Here, we present a case of a 72-year-old African American woman who presented to the hospital with shortness of breath and precordial chest pain for three days. The patient was diagnosed with volume overload associated with the progression of chronic kidney disease (CKD) and subsequently admitted to the hospital. Since the patient failed to adequately respond to diuretics, hemodialysis was initiated...
March 2024: Curēus
https://read.qxmd.com/read/38571837/the-silent-victims-how-the-israel-palestine-war-impacts-the-management-of-chronic-kidney-disease-and-end-stage-renal-disease-patients
#55
EDITORIAL
Abhi C Lohana, Amit Gulati, Jatender Kumar, Fnu Shivani, Danesh Kumar
This article discusses the multifaceted impact of wars and armed conflicts on healthcare systems, with a focus on the Israel-Palestine war and its consequences for individuals with chronic kidney disease (CKD) and end-stage renal disease (ESRD). The war has severely disrupted healthcare infrastructure, leading to damage or destruction of hospitals and clinics, shortages in medical supplies and staff, and interruptions in the delivery of essential services. This disruption poses significant challenges for the management of chronic conditions such as CKD and ESRD, where patients rely on regular and specialized care...
March 2024: Curēus
https://read.qxmd.com/read/38571671/a-case-of-chronic-kidney-disease-patient-with-rapid-deterioration-of-renal-function-hair-loss-and-spontaneous-resolution-of-facial-warts-after-covid-19-infection
#56
Qishun Wu, Fei Gao, Tao Zhang, Shixi Zhang, Yun Bai, Bei Zhu, Lulu Guo, Zhenzhu Yong, Weihong Zhao, Xiaohua Pei
BACKGROUND: Individuals with pre-existing chronic kidney disease (CKD) are at an increased risk of experiencing severe symptoms if infected with COVID-19. This report presents the case of a patient with CKD who contracted COVID-19 and subsequently experienced rapid deterioration of kidney function, hair loss, and spontaneous remission of facial warts. CASE PRESENTATION: A 60-year-old Chinese man with a decade-long history of abnormal serum creatinine (Scr) levels and recently heightened fatigue sought treatment...
February 2024: Aging medicine
https://read.qxmd.com/read/38568326/aa-amyloidosis-a-contemporary-view
#57
REVIEW
Safak Mirioglu, Omer Uludag, Ozge Hurdogan, Gizem Kumru, Ilay Berke, Stavros A Doumas, Eleni Frangou, Ahmet Gul
PURPOSE OF REVIEW: Amyloid A (AA) amyloidosis is an organ- or life-threatening complication of chronic inflammatory disorders. Here, we review the epidemiology, causes, pathogenesis, clinical features, and diagnostic and therapeutic strategies of AA amyloidosis. RECENT FINDINGS: The incidence of AA amyloidosis has declined due to better treatment of the underlying diseases. Histopathological examination is the gold standard of diagnosis, but magnetic resonance imaging can be used to detect cardiac involvement...
April 3, 2024: Current Rheumatology Reports
https://read.qxmd.com/read/38567242/comparative-analysis-of-demographic-and-clinical-findings-in-spontaneous-peritoneal-dialysis-related-and-secondary-bacterial-peritonitis
#58
JOURNAL ARTICLE
Tülay Unver Ulusoy, Hanife Nur Karakoç Parlayan, Nilgün Altın, Büşra Sarıkaya, Büşra Öztürk, İrfan Şencan
Background This study aims to contribute to peritonitis management strategies by comparing the demographic, clinical, and laboratory characteristics of patients diagnosed with spontaneous bacterial peritonitis (SBP), peritoneal dialysis-related peritonitis (PDrP), and secondary peritonitis. Methods This study included 86 patients diagnosed with peritonitis between 2016 and 2022. Patients were categorized and compared as SBP, PDrP, and secondary peritonitis. Results SBP was diagnosed in 36% of patients, secondary peritonitis in 36% and PDrP in 28%...
March 2024: Curēus
https://read.qxmd.com/read/38567102/short-versus-long-acting-erythropoiesis-stimulating-agents-for-anemia-management-in-egyptian-hemodialysis-patients
#59
JOURNAL ARTICLE
Amira Elsawy Soliman, Salma Magdy, Hazem Sayed Ayoub, Abdel-Hameed Ibrahim Ebid
BACKGROUND: Chronic kidney disease (CKD) often results in renal anemia, impacting the well-being of patients and causing various negative consequences. Erythropoiesis-stimulating agents (ESAs) offer promising solutions for managing anemia in CKD. This study aimed to evaluate and compare the effectiveness, safety profile, and cost-effectiveness of short-acting (Eprex® ) and long-acting (Aranesp® ) ESAs. METHOD: This comparative prospective cohort cost-effectiveness study was carried out over 6 months among adult Egyptian hemodialysis patients of either gender...
2024: Qatar Medical Journal
https://read.qxmd.com/read/38565198/managing-dry-skin-in-patients-with-comorbidities-or-with-advanced-age-unmet-needs-and-roles-for-products-containing-potential-emollient-plus-ingredients
#60
REVIEW
Matthias Augustin, Enzo Berardesca, Ulrike Blume-Peytavi, Peter Elsner, Davide Scafa, Leonard Christopher Schmeel, Ehrhardt Proksch
In dry skin (DS), skin-barrier function is easily disturbed and moisturizing factors in the stratum corneum are reduced. Despite being a common condition, DS is often overlooked in patients with advanced age or comorbid diseases. In September 2022, specialists in dermatology and skin care met to discuss unmet needs and management of patients with DS with existing medical conditions or DS induced by ongoing pharmacological treatments. There was consensus about the need to improve the current understanding and management of DS in patients with comorbidities, including type 2 diabetes, chronic kidney disease, radiodermatitis, and photodamaged skin...
December 2024: Journal of Dermatological Treatment
keyword
keyword
19480
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.